WO2009023047A3 - Methods for the directed expansion of epitopes for use as antibody ligands - Google Patents

Methods for the directed expansion of epitopes for use as antibody ligands Download PDF

Info

Publication number
WO2009023047A3
WO2009023047A3 PCT/US2008/005919 US2008005919W WO2009023047A3 WO 2009023047 A3 WO2009023047 A3 WO 2009023047A3 US 2008005919 W US2008005919 W US 2008005919W WO 2009023047 A3 WO2009023047 A3 WO 2009023047A3
Authority
WO
WIPO (PCT)
Prior art keywords
epitopes
methods
antibodies
antibody ligands
directed expansion
Prior art date
Application number
PCT/US2008/005919
Other languages
French (fr)
Other versions
WO2009023047A2 (en
Inventor
Dustan Bonnin
Original Assignee
Peptimmune Inc
Dustan Bonnin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Peptimmune Inc, Dustan Bonnin filed Critical Peptimmune Inc
Priority to MX2009012085A priority Critical patent/MX2009012085A/en
Priority to AU2008287530A priority patent/AU2008287530A1/en
Priority to CA002686817A priority patent/CA2686817A1/en
Priority to BRPI0811293A priority patent/BRPI0811293A2/en
Priority to US12/451,323 priority patent/US20100298547A1/en
Priority to EP08827320A priority patent/EP2157980A2/en
Priority to JP2010507464A priority patent/JP2010540410A/en
Priority to CN200880023441A priority patent/CN101848731A/en
Publication of WO2009023047A2 publication Critical patent/WO2009023047A2/en
Publication of WO2009023047A3 publication Critical patent/WO2009023047A3/en
Priority to IL201997A priority patent/IL201997A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C07K1/047—Simultaneous synthesis of different peptide species; Peptide libraries
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

The instant invention comprises a process for selecting and manufacturing antibodies useful for therapeutic, prophylactic, diagnostic or research purposes using epitope peptide mixtures synthesized by the solid phase synthesis, such process defined by a set of rules regarding the identity and the frequency of occurrence of amino acids that substitute a base or native amino acid of a known epitope. The resulting antibodies are related to but distinct from antibodies that bind to the known epitope.
PCT/US2008/005919 2007-05-07 2008-05-07 Methods for the directed expansion of epitopes for use as antibody ligands WO2009023047A2 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
MX2009012085A MX2009012085A (en) 2007-05-07 2008-05-07 Methods for the directed expansion of epitopes for use as antibody ligands.
AU2008287530A AU2008287530A1 (en) 2007-05-07 2008-05-07 Methods for the directed expansion of epitopes for use as antibody ligands
CA002686817A CA2686817A1 (en) 2007-05-07 2008-05-07 Methods for the directed expansion of epitopes for use as antibody ligands
BRPI0811293A BRPI0811293A2 (en) 2007-05-07 2008-05-07 methods for direct expansion of epitopes for use with antibody ligands.
US12/451,323 US20100298547A1 (en) 2007-05-07 2008-05-07 Methods for the directed expansion of epitopes for use as antibody ligands
EP08827320A EP2157980A2 (en) 2007-05-07 2008-05-07 Methods for the directed expansion of epitopes for use as antibody ligands
JP2010507464A JP2010540410A (en) 2007-05-07 2008-05-07 Method for directed expansion of epitopes for use as antibody ligands
CN200880023441A CN101848731A (en) 2007-05-07 2008-05-07 Methods for the directed expansion of epitopes for use as antibody ligands
IL201997A IL201997A0 (en) 2007-05-07 2009-11-08 Methods for the directed expansion of epitopes for use as antibody ligands

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US92822507P 2007-05-07 2007-05-07
US60/928,225 2007-05-07
US99928307P 2007-10-16 2007-10-16
US99928407P 2007-10-16 2007-10-16
US60/999,283 2007-10-16
US60/999,284 2007-10-16
US12468908P 2008-04-17 2008-04-17
US61/124,689 2008-04-17

Publications (2)

Publication Number Publication Date
WO2009023047A2 WO2009023047A2 (en) 2009-02-19
WO2009023047A3 true WO2009023047A3 (en) 2009-05-28

Family

ID=40351332

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/005919 WO2009023047A2 (en) 2007-05-07 2008-05-07 Methods for the directed expansion of epitopes for use as antibody ligands

Country Status (11)

Country Link
US (1) US20100298547A1 (en)
EP (1) EP2157980A2 (en)
JP (1) JP2010540410A (en)
KR (1) KR20100019487A (en)
CN (1) CN101848731A (en)
AU (1) AU2008287530A1 (en)
BR (1) BRPI0811293A2 (en)
CA (1) CA2686817A1 (en)
IL (1) IL201997A0 (en)
MX (1) MX2009012085A (en)
WO (1) WO2009023047A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008311897B2 (en) * 2007-10-16 2015-03-26 Declion Holdings Llc Methods for designing and preparing vaccines comprising directed sequence polymer compositions via the directed expansion of epitopes
CA2759118A1 (en) * 2008-04-17 2009-10-22 Declion Pharmaceuticals, Inc. Design and synthesis of directed sequence polymer compositions and antibodies thereof for the treatment of protein conformational disorders
EP2494062B1 (en) * 2009-10-28 2016-12-28 Janssen Biotech, Inc. Anti-glp-1r antibodies and their uses
KR101694523B1 (en) 2015-07-01 2017-01-23 박성진 Cctv camera bracket for notifying danger
CN111363043B (en) * 2020-04-09 2021-07-23 福州迈新生物技术开发有限公司 anti-CD 20 protein monoclonal antibody, cell line, preparation method and application thereof
CN112661816B (en) * 2021-01-13 2022-10-11 江西省人民医院 Artificial antigen and kit for detecting blood concentration of rituximab

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020183484A1 (en) * 1998-10-09 2002-12-05 Torres Jose V. Immunogenic formulation and process for preparation thereof
WO2006128294A1 (en) * 2005-06-01 2006-12-07 Variation Biotechnologies Inc. Peptide-based influenza vaccine formulation

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5859204A (en) * 1992-04-07 1999-01-12 Emory University Modified factor VIII
WO1995007707A1 (en) * 1993-09-14 1995-03-23 Cytel Corporation Alteration of immune response using pan dr-binding peptides
US6093396A (en) * 1996-09-27 2000-07-25 Diamyd Therapeutics Ab Modified glutamic acid decarboxylase (GAD)
FR2765688B1 (en) * 1997-07-04 1999-09-10 Pasteur Institut REAGENT FOR DETECTION AND MONITORING OF INFECTIONS CAUSED BY THE EPSTEIN-BARR VIRUS AND ITS APPLICATIONS
US6541011B2 (en) * 1998-02-11 2003-04-01 Maxygen, Inc. Antigen library immunization
IL157073A0 (en) * 2001-01-24 2004-02-08 Harvard College Therapeutic peptides for demyelinating conditions
JP2004085206A (en) * 2002-08-22 2004-03-18 Ajinomoto Co Inc Method for specifying disease-related amino acid residual group using interaction interface information between proteins, and method for screening medicine using the same
AT412785B (en) * 2003-12-04 2005-07-25 Kungl Andreas J Dr GAG BINDING PROTEINS
DE102004041964B4 (en) * 2004-08-04 2012-04-26 Schaeffler Technologies Gmbh & Co. Kg Machine element for rolling load
EP1676859A1 (en) * 2004-12-30 2006-07-05 Pevion Biotech Ltd. Immunogenic compositions of cyclic peptides derived from the beta-amyloid peptide
US20090162383A1 (en) * 2006-12-26 2009-06-25 Padlan Eduardo A Method for designing vaccines against constantly mutating pathogens

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020183484A1 (en) * 1998-10-09 2002-12-05 Torres Jose V. Immunogenic formulation and process for preparation thereof
WO2006128294A1 (en) * 2005-06-01 2006-12-07 Variation Biotechnologies Inc. Peptide-based influenza vaccine formulation

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
ANDERSON D E ET AL: "Overcoming original (antigenic) sin", CLINICAL IMMUNOLOGY, ACADEMIC PRESS, US, vol. 101, no. 2, 1 November 2001 (2001-11-01), pages 152 - 157, XP002225146, ISSN: 1521-6616 *
BIANCHI ELISABETTA ET AL: "Universal influenza B vaccine based on the maturational cleavage site of the hemagglutinin precursor", JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 79, no. 12, 1 June 2005 (2005-06-01), pages 7380 - 7388, XP002445847, ISSN: 0022-538X *
CARLOS M P ET AL: "Immunogenicity of a vaccine preparation representing the variable regions of the HIV type 1 envelope glycoprotein", AIDS RESEARCH AND HUMAN RETROVIRUSES, MARY ANN LIEBERT, US, vol. 16, no. 2, 20 January 2000 (2000-01-20), pages 153 - 161, XP002224415, ISSN: 0889-2229 *
MEYER D ET AL: "HYPERVARIABLE EPITOPE CONSTRUCTS REPRESENTING VARIABILITY IN ENVELOPE GLYCOPROTEIN OF SIV INDUCE A BROAD HUMORAL IMMUNE RESPONSEIN RABBITS AND RHESUS MACAQUES", AIDS RESEARCH AND HUMAN RETROVIRUSES, MARY ANN LIEBERT, US, vol. 14, no. 9, 10 June 1998 (1998-06-10), pages 751 - 760, XP001021061, ISSN: 0889-2229 *
MEYER D ET AL: "INDUCTION OF CYTOTOXIC AND HELPER T CELL RESPONSES BY MODIFIED SIMIAN IMMUNODEFICIENCY VIRUS HYPERVARIABLE EPITOPE CONSTRUCTS", VIRAL IMMUNOLOGY, MARY ANN LIEBERT, INC., NEW YORK, US, vol. 12, no. 2, 1 January 1999 (1999-01-01), pages 117 - 129, XP009002712, ISSN: 0882-8245 *
MORRISON K L ET AL: "Combinatorial alanine-scanning", CURRENT OPINION IN CHEMICAL BIOLOGY, CURRENT BIOLOGY LTD, LONDON, GB, vol. 5, no. 3, 1 June 2001 (2001-06-01), pages 302 - 307, XP002325957, ISSN: 1367-5931 *
PANTOPHLET R ET AL: "Improved design of an antigen with enhanced specificity for the broadly HIV-neutralizing antibody b12.", PROTEIN ENGINEERING, DESIGN & SELECTION : PEDS OCT 2004, vol. 17, no. 10, October 2004 (2004-10-01), pages 749 - 758, XP002518059, ISSN: 1741-0126 *
PONS J ET AL: "Energetic analysis of an antigen/antibody interface: alanine scanning mutagenesis and double mutant cycles on the HyHEL-10/lysozyme interaction.", PROTEIN SCIENCE : A PUBLICATION OF THE PROTEIN SOCIETY MAY 1999, vol. 8, no. 5, May 1999 (1999-05-01), pages 958 - 968, XP002521752, ISSN: 0961-8368 *

Also Published As

Publication number Publication date
JP2010540410A (en) 2010-12-24
MX2009012085A (en) 2010-01-20
CN101848731A (en) 2010-09-29
CA2686817A1 (en) 2009-02-19
BRPI0811293A2 (en) 2017-05-16
EP2157980A2 (en) 2010-03-03
US20100298547A1 (en) 2010-11-25
IL201997A0 (en) 2010-06-16
AU2008287530A1 (en) 2009-02-19
KR20100019487A (en) 2010-02-18
WO2009023047A2 (en) 2009-02-19

Similar Documents

Publication Publication Date Title
WO2007120834A3 (en) Methods for designing and synthesizing directed sequence polymer compositions via the directed expansion of epitope permeability
WO2009023047A3 (en) Methods for the directed expansion of epitopes for use as antibody ligands
RU2020109412A (en) ANTIBODY-PYRROLOBENZODIAZEPINE CONJUGATE
MX2009006199A (en) Abeta antibody parenteral formulation.
WO2008098917A3 (en) Novel antibodies against igf-ir
WO2011147982A3 (en) Monoclonal antibodies against her2 epitope
MX359384B (en) Improved assembly of bispecific antibodies.
WO2012125733A3 (en) Antibody screening methods
WO2010037836A3 (en) Cross-species-specific psmaxcd3 bispecific single chain antibody
EP3210625A3 (en) Therapeutic peptides comprising antibodies binding to mhc class 1 polypeptide related sequence a (mica)
IL186671A (en) Monoclonal antibodies that specifically bind to an amyloid-beta peptide, methods for producing them, pharmaceutical compositions comprising same and use thereof for the manufacture of medicaments
NZ589302A (en) Design and synthesis of directed sequence polymer compositions and antibodies thereof for the treatment of protein conformational disorders
WO2006094192A3 (en) Humanized l243 antibodies
WO2009004822A1 (en) ANTI-Muc17 ANTIBODY
WO2009015842A3 (en) Novel immunogenic epitopes for immunotherapy
WO2006021955A3 (en) Use of bat monoclonal antibody for immunotherapy
MX2012007153A (en) Novel antagonist antibodies and their fab fragments against gpvi and uses thereof.
WO2009074483A3 (en) Insulinotropic peptide synthesis using solid and solution phase combination techniques
WO2006050949A3 (en) Superagonistic anti-cd28 antibody
EA201070539A1 (en) NEW ANTIBODIES SPECIFIC TO β-AMYLOID PEPTIDES, AND THEIR USE AS DIAGNOSTIC OR MEDICINES
WO2006116442A3 (en) Monoclonal antibodies and methods for their use in the detection of cervical disease
MX2010001237A (en) Novel antibodies.
WO2009130459A3 (en) Epitopes of il-17a and il-17f and antibodies specific thereto
WO2010124163A3 (en) Granulocyte-macrophage colony-stimulating factor (gm-csf) neutralizing antibodies
WO2006091421A3 (en) Peptides for detection of antibody to ehrlichia ewingii

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880023441.6

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08827320

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2686817

Country of ref document: CA

Ref document number: 2010507464

Country of ref document: JP

Ref document number: MX/A/2009/012085

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 7251/DELNP/2009

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2008287530

Country of ref document: AU

Ref document number: 581190

Country of ref document: NZ

ENP Entry into the national phase

Ref document number: 20097025559

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2008827320

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2008287530

Country of ref document: AU

Date of ref document: 20080507

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 12451323

Country of ref document: US

ENP Entry into the national phase

Ref document number: PI0811293

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20091109